BDBM325543 US10189845, Example 205A::US10189845, Example 206B::US11028093, Example 206

SMILES CCC(CC1CC1)n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(C[C@@H](O)CO)c1

InChI Key InChIKey=FISCYOFARSRLSI-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 325543   

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 10nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/29/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM325543(US10189845, Example 206B | US10189845, Example 205...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent